Related Experiment Video
Updated: Mar 3, 2026

Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
Xanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in mice
Raquel Costa1, Ilda Rodrigues2, Luísa Guardão3
1Department of Biochemistry, Faculty of Medicine of the University of Porto, Porto, Portugal; i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Abstract:
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by metabolic disturbances in specific tissues. The present work aimed to analyze the effects of xanthohumol (XN) and 8-prenylnaringenin (8PN), two beer-derived polyphenols, in liver and skeletal muscle lipid and glycolytic metabolism in T2DM mice model. Thirty C57Bl/6 mice were randomly divided into five groups: standard diet (control), high-fat diet (DM), high-fat diet plus ethanol (DM-Ethanol), high-fat diet plus 10 mg/L XN (DM-XN) and high-fat diet plus 10 mg/L 8PN (DM-8PN) during 20 weeks. Fasting blood glucose and insulin tolerance tests were performed 1 week before sacrifice. At the end of the study, blood, liver and skeletal muscle were collected. Both XN and 8PN treatments prevented body weight gain; decreased glycemia, triglyceride, cholesterol and alkaline phosphatase levels; and improved insulin sensitivity. Polyphenols promoted hepatic and skeletal muscle AMP-activated protein kinase (AMPK) activation, diminishing the expression of target lipogenic enzymes (sterol regulatory element binding protein-1c and fatty acid synthase) and acetyl-CoA carboxylase activity. Moreover, both XN and 8PN treatments decreased VEGFR-1/VEGFB pathway, involved in fatty acid uptake, and increased AS160 expression, involved in GLUT4 membrane translocation. Presented data demonstrated that both XN and 8PN treatment resulted in AMPK signaling pathway activation, thus suppressing lipogenesis. Their consumption prevented body weight gain and improved plasma lipid profile, with significant improvement of insulin resistance and glucose tolerance. XN- or 8PN-enriched diet could ameliorate diabetic-associated metabolic disturbances by regulating glucose and lipid pathways.
Insights
Beer compounds xanthohumol (XN) and 8-prenylnaringenin (8PN) activate AMPK signaling, reducing lipogenesis and improving metabolic health. These polyphenols helped prevent weight gain and enhance insulin sensitivity in diabetic mice.
Area of Science:
- Biochemistry
- Metabolic Diseases
- Nutraceuticals
Background:
- Type 2 diabetes mellitus (T2DM) involves chronic metabolic disturbances.
- Beer-derived polyphenols like xanthohumol (XN) and 8-prenylnaringenin (8PN) show potential therapeutic benefits.
- Understanding their impact on liver and skeletal muscle metabolism is crucial for T2DM management.
Purpose of the Study:
- To investigate the effects of XN and 8PN on lipid and glycolytic metabolism in a T2DM mouse model.
- To analyze the molecular mechanisms underlying polyphenol action in liver and skeletal muscle.
Main Methods:
- A 20-week study involving C57Bl/6 mice divided into control, T2DM, and T2DM groups supplemented with ethanol, XN, or 8PN.
- Assessment of body weight, glucose levels, insulin tolerance, and lipid profiles.
- Analysis of key metabolic pathways, including AMPK signaling, lipogenesis, and glucose transport.
Main Results:
- XN and 8PN treatments prevented weight gain and improved glucose tolerance and insulin sensitivity.
- Polyphenols activated AMPK, suppressed lipogenic enzyme expression, and reduced triglyceride and cholesterol levels.
- Decreased VEGFR-1/VEGFB pathway activity and increased AS160 expression were observed, facilitating fatty acid uptake and glucose transport.
Conclusions:
- XN and 8PN activate the AMPK signaling pathway, suppressing lipogenesis and ameliorating T2DM-associated metabolic disturbances.
- Dietary intake of XN or 8PN can improve plasma lipid profiles and enhance glucose metabolism.
- These findings highlight the potential of beer-derived polyphenols as a therapeutic strategy for managing T2DM.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...

